Search

Objectives: This study aims to evaluate the levels of serum endocan in children with juvenile idiopathic arthritis (JIA). Patients and methods: Sixty-seven children with JIA (30 males, 37 females; mean age 10.4±4.9 years; range 2 to 18 years) and a sex- and agematched healthy control group of 39 children (16 males, 23 females; mean age 9.3±4.1 years; range 1 to 17 years) were recruited. Patients with JIA were divided into two groups as the clinically active JIA group (n=27) and inactive JIA group (n=40). Results: The median serum endocan level in patients with JIA was significantly higher than in the control group (633.75 ng/L vs. 379.76 ng/L, p<0.01). Comparison between patients with active JIA and inactive JIA was not significant in terms of endocan levels (618.70 ng/L vs. 687.36 ng/L, p=0.34). There was a weak negative correlation between Childhood Health Assessment Questionnaire scores of patients with JIA and serum endocan levels. Conclusion: The high level of serum endocan highlighted the endothelial damage in patients with JIA. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate intraocular pressure (IOP) changes after single administration of dexamethasone implant (DI). Methods: 1110 eyes of 1110 patients were included in this retrospective study. 726 eyes had DME, 262 eyes had macular edema secondary to branch retinal vein occlusion, and 122 eyes had macular edema secondary to central retinal vein occlusion. Data were collected at baseline, and each monthly visit. All adverse events during DI injection and during 6-month follow-up were recorded. IOP was measured at baseline and each visit. Results: The mean ages was 61.6±8.5 year (range: 22-88 years). There was no significant differences in mean IOP measurements among values taken prior to injection and during each monthly visit afterward (p>.050). 168 eyes had IOP values of more than 20 mmHg during the follow-up period in general. 98 eyes did not receive any treatment, 65 eyes were treated with topical drops. 5 eyes were treated with selective laser trabeculoplasty. No surgery was required for any patient. No systemic adverse event observed. Conclusion: DI injection may not carry a big risk of IOP rising in first 6 months. Also there may be no systemic adverse events associated with DI injection in first 6 months. [ABSTRACT FROM AUTHOR]